PCIDB

KNApSAcK Metabolite C00002513

Metabolite

KNApSAcK Entry

id C00002513
Name Cajanol
CAS RN 61020-70-0
Standard InChI InChI=1S/C17H16O6/c1-21-10-6-13(19)16-15(7-10)23-8-12(17(16)20)11-4-3-9(18)5-14(11)22-2/h3-7,12,18-19H,8H2,1-2H3
Standard InChI (Main Layer) InChI=1S/C17H16O6/c1-21-10-6-13(19)16-15(7-10)23-8-12(17(16)20)11-4-3-9(18)5-14(11)22-2/h3-7,12,18-19H,8H2,1-2H3

Cluster

Phytochemical cluster No. 14
KCF-S cluster No. 106

Link

ChEMBL

By standard InChI
By standard InChI Main Layer CHEMBL1689287

KEGG

By LinkDB C10204

CTD

By CAS RN C471767

Human Protein / Gene in interaction

CTD interaction (16)

compound gene gene name gene description interaction interaction type form reference
pmid
C471767 581 BAX
BCL2L4
BCL2-associated X protein [[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein affects cotreatment
/ affects localization
/ decreases expression
/ increases expression
protein 20638373
C471767 581 BAX
BCL2L4
BCL2-associated X protein [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP3 protein affects cotreatment
/ affects localization
/ decreases expression
/ increases activity
/ increases expression
protein 20638373
C471767 581 BAX
BCL2L4
BCL2-associated X protein [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP9 protein affects cotreatment
/ affects localization
/ decreases expression
/ increases activity
/ increases expression
protein 20638373
C471767 581 BAX
BCL2L4
BCL2-associated X protein cajanol results in increased expression of BAX protein increases expression
protein 20638373
C471767 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 cajanol results in decreased expression of BCL2 protein decreases expression
protein 20638373
C471767 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein affects cotreatment
/ affects localization
/ decreases expression
/ increases expression
protein 20638373
C471767 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP3 protein affects cotreatment
/ affects localization
/ decreases expression
/ increases activity
/ increases expression
protein 20638373
C471767 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP9 protein affects cotreatment
/ affects localization
/ decreases expression
/ increases activity
/ increases expression
protein 20638373
C471767 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP3 protein affects cotreatment
/ affects localization
/ decreases expression
/ increases activity
/ increases expression
protein 20638373
C471767 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) cajanol results in increased activity of CASP3 protein increases activity
protein 20638373
C471767 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP9 protein affects cotreatment
/ affects localization
/ decreases expression
/ increases activity
/ increases expression
protein 20638373
C471767 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) cajanol results in increased activity of CASP9 protein increases activity
protein 20638373
C471767 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic cajanol affects the localization of CYCS protein affects localization
protein 20638373
C471767 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic [[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein affects cotreatment
/ affects localization
/ decreases expression
/ increases expression
protein 20638373
C471767 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP3 protein affects cotreatment
/ affects localization
/ decreases expression
/ increases activity
/ increases expression
protein 20638373
C471767 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP9 protein affects cotreatment
/ affects localization
/ decreases expression
/ increases activity
/ increases expression
protein 20638373

Related Disease

Diseases related to CTD interactions

1 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D001943 C471767 Breast Neoplasms therapeutic
20638373